Examples: breast cancer, NCT03147287, pd-l1

Top 100 results for: "prostate cancer"

Not Enrolling

An open-label phase 1b study to determine the maximum tolerated and/or recommended phase 2 dose of the ATR inhibitor elimusertib (BAY 1895344) in combination with PARP inhibitor niraparib, in participants with recurrent advanced solid tumors and ovarian cancer

Trial Description: The purpose of the study is to test how well patients with advanced solid tumors and ovarian cancer respond to treatment with elimusertib in combination with niraparib. In addition researchers want to find for patients the optimal dose of elimusertib in combination with niraparib, how the drug is tolerated and the way the body absorbs, distributes and discharges the drug. The study medication elimusertib works by blocking a substance produced by the body (ATR Kinase) which is important for the growth of tumor cells. Niraparib works by blocking a substance produced by the body (PARP enzymes) in a way that tumor cells can be killed, or made more susceptible to chemotherapy.

  • Conditions: advanced solid tumors (excluding prostate cancer), ovarian cancer
  • Phase: I/II
  • Trial ID: NCT04267939
  • Protocol ID: 19-810

Enrolling

Judging MR Simulation Procedures: A Phase I-II Study of the Use of Magnetic Resonance Imaging Simulation in the Planning of Radiation Treatments (JUMP)

Trial Description: This is a master protocol for a prospective Phase I-II study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatments

  • Conditions: head and neck cancer, liver cancer, prostate cancer, recurrent adenocarcinoma
  • Phase: I/II
  • Trial ID: NCT04545957
  • Protocol ID: 19-759

Not Enrolling

A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Trial Description: An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC

  • Conditions: acinic cell tumor, adenoid cystic carcinoma, genital neoplasms male, metastatic castration-resistant prostate cancer, mucoepidermoid carcinoma, neoplasms, neoplasms by histologic type, neoplasms by site, neoplasms prostate, prostate cancer, prostatic disease, prostatic neoplasms, prostatic neoplasms castration-resistant, salivary duct carcinoma, salivary gland cancer, salivary gland tumor, urogenital neoplasms
  • Phase: I
  • Trial ID: NCT04249947
  • Protocol ID: 20-075

Not Enrolling

A Phase 1/2 Study of CT7001 in Combination with Fulvestrant in Patients with Metastatic or Locally Advanced Hormone-Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Trial Description: This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in advanced solid malignancies and to further investigate CT7001 as monotherapy or in combination with standard therapy in specific participant groups with Triple Negative Breast Cancer (TNBC), Castrate Resistant Prostate Cancer (CRPC) and in combination with fulvestrant for patients with hormone receptor-positive (HR+ve) / human epidermal growth factor-2 negative (HER2-ve) breast cancer.

  • Conditions: advanced solid malignancies
  • Phase: I/II
  • Trial ID: NCT03363893
  • Protocol ID: 19-827

Not Enrolling

A Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Trial Description: NUV-422-02 is a first-in-human, open-label, Phase 1/2 dose escalation and multiple expansion cohort study designed to evaluate the safety and efficacy of NUV-422. The study population is comprised of adults with recurrent or refractory high-grade gliomas (HGGs), metastatic breast cancer (mBC), with and without brain metastases, and recurrent or refractory metastatic castration-resistant prostate cancer (mCRPC). All patients will self-administer NUV-422 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.

  • Conditions: advanced breast cancer, advanced breast carcinoma, breast cancer, breast carcinoma, breast tumor, cancer of breast, cancer of prostate, cancer of the breast, cancer of the prostate, castrate resistant prostate cancer, castration resistant prostatic neoplasms, castration-resistant prostate cancer, glial cell tumors, glioblastoma, glioma, glioma malignant, glioma mixed, malignant tumor of breast, metastatic breast cancer, metastatic breast carcinoma, prostate cancer, prostate neoplasm, prostatic cancer, recurrent glioblastoma
  • Phase: I/II
  • Trial ID: NCT04541225
  • Protocol ID: 20-517

Enrolling

A Randomized Control trial of Telemedicine vs In Person Oncology Patient Surveillance

Trial Description: This research study is comparing telemedicine and face-to-face visits to understand patients' experiences with telemedicine versus face to face visits and to understand when it is and is not appropriate to conduct visits remotely

  • Conditions: breast cancer, patient engagement, patient preference, patient satisfaction, prostate cancer
  • Phase: Not Applicable
  • Trial ID: NCT04936243
  • Protocol ID: 21-192

Enrolling

A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PF-07220060 as a Single Agent and as Part of Combination Therapy in Participants with Advanced Solid Tumors

Trial Description: This is a Phase 1, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and then in combination with endocrine therapy. In Part 1A, single escalating doses of PF-07220060 alone will be administered to determine the maximum tolerated dose (MTD) and select the recommended phase 2 dose (RP2D). In Part 1B and Part 1C, PF-07220060 will be administered in combination with 1 of 2 endocrine therapies (letrozole and fulvestrant, respectively). In Part 1D, food effect

  • Conditions: adenocarcinoma of lung, breast neoplasms, crc, liposarcoma, prostate cancer, solid tumors
  • Phase: I
  • Trial ID: NCT04557449
  • Protocol ID: 20-664

Not Enrolling

A phase IB open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprivation therapy and other agents in subjects with castrate resistant prostate cancer (CRPC).

Trial Description: This study aims to evaluate the combination of GSK525762 with other agents that have been shown to be effective in the treatment of CRPC or metastatic (m)CRPC. This study is designed to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) based on safety, tolerability, pharmacokinetic, and efficacy profiles of GSK525762 in combination with either abiraterone (Arm A) or enzalutamide (Arm B

  • Conditions: solid tumours
  • Phase: I
  • Trial ID: NCT03150056
  • Protocol ID: 17-369

Not Enrolling

PSMAfore: A phase III, Open-label, Multi-center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate Cancer

Trial Description: The purpose of this study is to determine whether 177Lu-PSMA-617 improves the rPFS or death compared to a change in ARDT in mCRPC participants that were previously treated with an alternate ARDT and not exposed to a taxane-containing regimen in the CRPC or mHSPC settings. Approximately 450 participants will be randomized (225 per treatment group

  • Conditions: prostatic neoplasms
  • Phase: III
  • Trial ID: NCT04689828
  • Protocol ID: 21-193

Not Enrolling

A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with

Trial Description: The purpose of this study is to assess the efficacy and safety of the combination of the polyadenosine 5'-diphosphoribose poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and pembrolizumab in the treatment of participants with mCRPC who have failed to respond to either abiraterone acetate or enzalutamide (but not both) and to chemotherapy. The primary study hypotheses are that the combination of pembrolizumab plus olaparib is superior to abiraterone acetate or enzalutamide with respect to: 1. Overall Survival (OS) and 2. Radiographic progression-free survival (rPFS) per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 as assessed by blinded independent central review (BICR)

  • Conditions: prostatic neoplasms
  • Phase: III
  • Trial ID: NCT03834519
  • Protocol ID: 19-456

Not Enrolling

A Phase 1, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects with Advanced Solid Tumors

Trial Description: This is a Phase 1/2, open-label, multi-center, non-randomized, dose-escalation study to be conducted in two parts: the Dose Escalation Phase and the Dose Expansion Phase. The Dose Escalation Phase will determine the Maximum Tolerated Dose (MTD) and recommended Phase 2 dose(s) (RP2D) of PT-112 Injection and evaluate its safety and tolerability, and PK (pharmacokinetics). The Dose Escalation Phase is no longer enrolling. The Dose Expansion Phase has two cohorts: one cohort for the study of PT-112 in patients with thymoma and thymic carcinoma (Cohort A), and one cohort for the study of PT-112 in metastatic castrate-resistant prostate cancer (mCRPC) (Cohort D).

  • Conditions: advanced solid tumors, crpc, genital neoplasms male, mcrpc, metastatic castrate-resistant prostate cancer, neoplasms by site, prostatic neoplasms, pt-112, urogenital neoplasms
  • Phase: I/II
  • Trial ID: NCT02266745
  • Protocol ID: 20-558

Enrolling

Video Education with Result Dependent dIsclosure (VERDI)

Trial Description: The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.

  • Conditions: breast cancer, colorectal cancer, genetic testing, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, sarcoma
  • Phase: Not Applicable
  • Trial ID: NCT05225428
  • Protocol ID: 21-508

Not Enrolling

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients with Unresectable or Metastatic Neoplasms

Trial Description: The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab. This Phase 1, open-label study will characterize safety, dose-limiting toxicities (DLTs), and maximum tolerated/administered dose (MTD/MAD) of MGD019. Dose escalation will occur in a 3+3+3 design in patients with advanced solid tumors of any histology. Once the MTD/MAD is determined, a Cohort Expansion Phase will be enrolled to further characterize safety and initial anti-tumor activity in patients with specific

  • Conditions: advanced cancer, colorectal cancer, cutaneous melanoma, prostate cancer metastatic, solid tumor adult, squamous cell non small cell lung cancer
  • Phase: I
  • Trial ID: NCT03761017
  • Protocol ID: 19-090

Enrolling

A DOSE ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XL102 AS SINGLE-AGENT AND COMBINATION THERAPY IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

Trial Description: This is a Phase 1, open-label, dose-escalation and expansion study evaluating the safety, tolerability, PK, antitumor activity, and effect on biomarkers of XL102 administered orally alone and in multiple combination regimens to subjects with advanced solid tumors

  • Conditions: epithelial ovarian cancer, hormone receptor positive breast carcinoma, metastatic castration-resistant prostate cancer, neoplasm malignant, triple negative breast cancer
  • Phase: I
  • Trial ID: NCT04726332
  • Protocol ID: 21-057

Enrolling

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

Trial Description: This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors

  • Conditions: colorectal cancer, hormone receptor positive breast carcinoma, metastatic castration-resistant prostate cancer, neoplasm malignant, renal cell carcinoma, urothelial carcinoma
  • Phase: I
  • Trial ID: NCT03845166
  • Protocol ID: 19-157

Not Enrolling

A Phase 1/1b Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

in selected patient populations. Patients anticipated to be enrolled in Phase 1b will be selected based upon having a tumor type, including but not limited to, non small cell lung cancer and head and neck cancer positive for specific activating MET, NTRK2, NTRK3, or DDR2 mutations, MET or KIT/PDGFRA/KDR gene amplification, selected gene rearrangements involving the MET, RET, AXL, NTRK1, or NTRK3 gene loci, or having loss of function mutations in the CBL gene. In addition patients with clear cell renal cell carcinoma refractory to angiogenesis inhibitors or metastatic prostate cancer with bone metastasis will be enrolled.

  • Conditions: advanced cancer
  • Phase: I
  • Trial ID: NCT02219711
  • Protocol ID: 14-308

Enrolling

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

Trial Description: This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, PK, preliminary antitumor activity, and effect of biomarkers of XL092 administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in subjects with advanced solid tumors. In the Expansion Stage, the safety and efficacy of XL092 as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts

  • Conditions: colorectal cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, metastatic castration-resistant prostate cancer, non-small cell lung cancer, renal cell carcinoma, solid tumor, urothelial carcinoma
  • Phase: I
  • Trial ID: NCT05176483
  • Protocol ID: 22-199

Not Enrolling

A phase II study of nivolumab combined with ipilimumab for patients with advanced rare genitourinary tumors

Trial Description: This research study is studying a combination of drugs as a possible treatment for rare genitourinary malignancies among four cohorts, bladder or upper tract carcinoma with variant histology, adrenocortical carcinoma, other rare genitourinary carcinomas and any genitourinary carcinoma with neuroendocrine differentiation. Given preliminary results, the study is being tested in additional patients with bladder or upper tract carcinoma with variant histology at this time while the adrenocortical carcinoma, other rare genitourinary malignancies arms have closed to accrual

  • Conditions: adrenocortical carcinoma, genitourinary cancer, high grade neuroendocrine carcinoma/small cell carcinoma, non-adenocarcinoma prostate cancer, non-urothelial bladder, non-urothelial upper tract, penile cancer, refractory germ-cell
  • Phase: II
  • Trial ID: NCT03333616
  • Protocol ID: 17-423

Enrolling

A Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)

Trial Description: This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. - The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. - Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures

  • Conditions: adrenal metastases, borderline resectable pancreatic carcinoma, brain metastases, liver metastases, lung cancer, mesothelioma, metachronous nodal metastases, oligoprogressive nodal metastases, pancreas cancer, prostate cancer, renal cancer, spine metastases, synchronous nodal metastases
  • Phase: I/II
  • Trial ID: NCT04115254
  • Protocol ID: 19-353

Not Enrolling

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

Trial Description: This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric cancer/gastroesophageal

  • Conditions: castration-resistant prostate cancer, colorectal cancer, differentiated thyroid cancer, endometrial cancer, gastric cancer, gastroesophageal junction adenocarcinoma, head and neck cancer, hepatocellular carcinoma, lower esophageal cancer, non-small cell lung cancer, ovarian cancer, renal cell carcinoma, triple negative breast cancer, urothelial carcinoma
  • Phase: I
  • Trial ID: NCT03170960
  • Protocol ID: 17-492

Not Enrolling

A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients with Unresectable or Metastatic B7-H3-Expressing Neoplasms and Neoplasms whose Vasculature Expresses B7-H3

Trial Description: The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely. Assessments will be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics (PD) and to evaluate potential anti-tumor activity of MGD009

  • Conditions: bladder cancer, breast cancer, clear cell renal cell carcinoma, colon cancer, melanoma, mesothelioma, non small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, soft tissue sarcoma, squamous cell carcinoma of the head and neck, thyroid cancer
  • Phase: I
  • Trial ID: NCT02628535
  • Protocol ID: 16-510

Not Enrolling

A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors

Trial Description: This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome proliferator activated receptor alpha) as monotherapy and in combination with a systemic anticancer agent, nivolumab, an anti-PD1 antibody, in subjects with advanced solid tumors

  • Conditions: cholangiocarcinoma, colorectal cancer, gastroesophageal cancer, hepatocellular carcinoma, metastatic castration resistant prostate cancer, non-small cell lung cancer, pancreatic cancer, renal cell carcinoma, sarcoma, squamous cell carcinoma of head and neck, triple-negative breast cancer, urothelial carcinoma
  • Phase: I
  • Trial ID: NCT03829436
  • Protocol ID: 19-741

Enrolling

A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors

Trial Description: This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as monotherapy or in combination with INCMGA00012 in participants with selected CD8 T-cell-positive advanced solid tumors including SCCHN, NSCLC, ovarian cancer, CRPC, TNBC, bladder cancer, and specified GI malignancies (defined as CRC, gastric/GEJ cancer, HCC, PDAC, or SCAC)

  • Conditions: bladder cancer, castration resistant prostate cancer, colorectal cancer, gastric/ gastroesophageal junction, hepatocellular carcinoma, non small cell lung cancer, ovarian cancer, pancreatic ductal adenocarcinoma, squamous carcinoma of the anal canal, squamous cell carcinoma of head and neck, triple negative breast cancer
  • Phase: I
  • Trial ID: NCT04580485
  • Protocol ID: 21-076

Not Enrolling

A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT, IN COMBINATION WITH CPI-444, AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS

Trial Description: This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers. CPI-006 will be evaluated as a single agent, in combination with ciforadenant (an oral adenosine 2A receptor antagonist), in combination with pembrolizumab (an anti-PD1 antibody), and in combination with ciforadenant and pembrolizumab.

  • Conditions: bladder cancer, cervical cancer, colorectal cancer, endometrial cancer, metastatic castration resistant prostate cancer, non-hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, renal cell cancer, sarcoma, squamous cell carcinoma of the head and neck, triple negative breast cancer
  • Phase: I
  • Trial ID: NCT03454451
  • Protocol ID: 18-335

Enrolling

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB/II Study

Trial Description: This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.

  • Conditions: adenoid cystic carcinoma, advanced solid tumor, cervical cancer, esophageal cancer, gastric cancer, gastroesophageal junction adenocarcinoma, metastatic breast cancer, metastatic colorectal cancer, metastatic head and neck carcinoma, metastatic melanoma, metastatic prostate cancer, metastatic renal cell carcinoma, non small cell lung cancer, ovarian cancer, pancreas cancer, salivary gland cancer, sarcomas, small cell lung cancer, urothelial carcinoma
  • Phase: I
  • Trial ID: NCT04140526
  • Protocol ID: 22-076

Not Enrolling

A Phase I-II, First-in-Human Study of A166 in Patients with Locally Advanced/Metastatic Solid Tumors which are Human Epidermal Growth Factor Receptor 2 (HER2)-Positive who did not Respond or Stopped Responding to Approved Therapies and Patients with HER2 Positive (by ISH or NGS) or Low Expressing (b

Trial Description: Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity

  • Conditions: bile duct cancer, bladder cancer, breast neoplasm malignant primary, cervical cancer, cholangiocarcinoma, colo-rectal cancer, head and neck cancer, head and neck carcinoma, her-2 gene amplification, her2 gene mutation, her2 positive gastric cancer, her2-positive breast cancer, larynx cancer, lip cancer stage i, liver cancer, lung cancer, mouth cancer, mucinous adenocarcinoma gastric, mucinous breast cancer recurrent, mucoepidermoid carcinoma, palate cancer, pancreatic cancer, primary peritoneal carcinoma, prostate cancer, rare diseases, rectal cancer, rectal cancer stage i, rectal cancer stage ii, rectal cancer stage iii, recurrent breast cancer, recurrent colon cancer, recurrent gastric cancer, recurrent ovarian carcinoma, recurrent prostate cancer, recurrent renal cell cancer, salivary gland cancer, salivary gland carcinoma, salivary gland neoplasms, salivary gland tumor, skin cancer, solid tumor, tongue cancer, tonsil cancer, urologic cancer
  • Phase: I/II
  • Trial ID: NCT03602079
  • Protocol ID: 18-421

Not Enrolling

Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions

Trial Description: The hypothesis of this study is that focal treatment with ExAblate MRgFUS has the potential to be an effective non-invasive treatment for intermediate risk, organ-confined prostate lesions, with a low incidence of morbidity. The study hypothesis will be tested by measuring treatment-related safety and initial effectiveness parameters in the ExAblate MRgFUS treated patients, as described above.

  • Conditions: localized intermediate risk prostate lesions
  • Phase: Feasibility / Pilot
  • Trial ID: NCT01657942
  • Protocol ID: 13-184

Enrolling

MTG201-MPM-001Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men with Cancer and Androgen Deficiency

Trial Description: This is a large randomized, double-blind, placebo-controlled trial to determine the efficacy of testosterone replacement on cancer-related fatigue in older men with incurable cancer who report fatigue and have low testosterone levels.

  • Conditions: cancer, fatigue, hypogonadism male
  • Phase: II
  • Trial ID: NCT04301765
  • Protocol ID: 20-183

Enrolling

A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Saftey, Tolerability, and Pharmacokinetics of HPN328 in Patients with Advanced Cancers Associated with Expression of Delta-Like Canonical Notch Ligand 3 (DLL3) Who Have Failed Standard Available Therapy.

Trial Description: An open-label, Phase 1/2 study of HPN328 as monotherapy to assess the safety, tolerability and PK in patients with advanced cancers associated with expression of DLL3.

  • Conditions: small-cell lung cancer
  • Phase: I/II
  • Trial ID: NCT04471727
  • Protocol ID: 20-751

Not Enrolling

A Phase 2 Study Evaluating Futibatinib (TAS-120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Trial Description: The purpose of the trial is to evaluate the antitumor activity and confirm the safety for the combination of Fibroblast Growth Factor Receptor (FGFR) inhibitor futibatinib and anti-programmed cell death-1 (PD-1) antibody pembrolizumab in patients with advanced or metastatic urothelial cancer who are not candidates to receive a platinum-based treatment regimens.

  • Conditions: advanced and metastatic urothelial cancer
  • Phase: II
  • Trial ID: NCT04601857
  • Protocol ID: 20-549

Enrolling

Sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma progressing on platinum-based chemotherapy and PD1/L1 inhibitors: the Double Antibody Drug conjugate (DAD) Phase I trial

Trial Description: This research study will assess what doses of Sacituzumab Govitecan and Enfortumab Vedotin can be safely combined in the treatment of metastatic urothelial carcinoma (mUC). The names of the study drugs in this investigational combination are: - Enfortumab Vedotin - Sacituzumab Govitecan

  • Conditions: bladder cancer, metastatic urothelial carcinoma, metastatic urothelial carcinoma of the renal pelvis and ureter, urothelial cancer
  • Phase: I
  • Trial ID: NCT04724018
  • Protocol ID: 20-614

Not Enrolling

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Trial Description: The purpose of this study was to compare the overall survival (OS) of participants with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV) to the OS of participants treated with chemotherapy. This study compared progression-free survival on study therapy (PFS1); the overall response rate (ORR) and the disease control rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 of participants treated with EV to participants treated with chemotherapy. In addition, this study evaluated the duration of response (DOR) per RECIST V1.1 of EV and chemotherapy and assessed the safety and tolerability of EV, as well as, the quality of life (QOL) and Patient Reported Outcomes (PRO) parameters.

  • Conditions: bladder cancer, ureteral cancer, urothelial cancer
  • Phase: III
  • Trial ID: NCT03474107
  • Protocol ID: 18-386

Not Enrolling

Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial (A031901)

Trial Description: This phase III trial compares survival in urothelial cancer patients who stop immune checkpoint inhibitor treatment after being treated for about a year to those patients who continue treatment with immune checkpoint inhibitors. Immunotherapy with monoclonal antibodies, such as avelumab, durvalumab, pembrolizumab, atezolizumab, and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stopping immune checkpoint inhibitors early may still make the tumor shrink and patients may have similar survival rates as the patients who continue treatment. Stopping treatment early may also lead to fewer treatment-related side effects, an improvement in mental health, and a lower cost burden to patients.

  • Conditions: locally advanced bladder urothelial carcinoma, locally advanced renal pelvis urothelial carcinoma, locally advanced ureter urothelial carcinoma, locally advanced urethral urothelial carcinoma, locally advanced urothelial carcinoma, metastatic bladder urothelial carcinoma, metastatic renal pelvis urothelial carcinoma, metastatic ureter urothelial carcinoma, metastatic urethral urothelial carcinoma, metastatic urothelial carcinoma
  • Phase: III
  • Trial ID: NCT04637594
  • Protocol ID: 21-392

Enrolling

Improving Patient-Important Outcomes with Testosterone Replacement in Hypogonadal Men with a Prior History of Cancer

Trial Description: The overall goal of this study is to evaluate the effect of a testosterone drug called Depo-Testosterone (or 'testosterone cypionate'), an FDA-approved drug for improving fatigue, sexual function, quality of life, body composition, muscle strength, and physical activity in young cancer survivors who report fatigue and have low testosterone. Main hypothesis is that Testosterone administration in young male cancer survivors who are in remission for at least 1 year, report cancer-related fatigue and have symptomatic testosterone deficiency will be associated with greater improvements in fatigue scores compared with placebo.

  • Conditions: fatigue syndrome chronic, hypogonadism male
  • Phase: II
  • Trial ID: NCT04049331
  • Protocol ID: 19-646

Not Enrolling

"FORCE: Focus on Reducing Dose-Limiting Toxicities in Colon Cancer with Resistance Exercise"

Trial Description: FORCE is a randomized home-based resistance training/strength training (RT) intervention study for Stage II and III colon cancer patients undergoing chemotherapy. Participants will be 180 newly diagnosed Stage II and III colon cancer patients from Kaiser Permanente of Northern California (KPNC), the Penn State Cancer Institute (PSCI), and the Dana Farber Cancer Institute (DFCI). The intervention will begin within the first weeks of adjuvant chemotherapy and continue exercise through the completion of post-operative chemotherapy. Specifically, the investigators will examine

  • Conditions: chemotherapy effect, colon cancer, resistance training
  • Phase: Not Applicable
  • Trial ID: NCT03291951
  • Protocol ID: 18-063

Not Enrolling

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Trial Description: In this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) therapy and who are considered ineligible for or have refused to undergo radical cystectomy, will receive pembrolizumab therapy or pembrolizumab in combination with other investigational agents. The primary study hypothesis is that treatment with pembrolizumab will result in a clinically meaningful response.

  • Conditions: bladder cancer
  • Phase: II
  • Trial ID: NCT02625961
  • Protocol ID: 17-133

Not Enrolling

A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients with Advanced or Metastatic Urothelial Carcinoma

Trial Description: The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma

  • Conditions: urothelial carcinoma, urothelial carcinoma bladder, urothelial carcinoma of the renal pelvis and ureter, urothelial carcinoma ureter, urothelial carcinoma urethra
  • Phase: II
  • Trial ID: NCT03606174
  • Protocol ID: 20-521

Not Enrolling

Phase II Trial of Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphomas

Trial Description: Ofatumumab is a drug that works by attaching to the CD20 molecule found on the surface of cancerous B cells, and then triggering the death of those cells. It is approved by the FDA for treatment of another B-cell cancer, chronic lymphocytic leukemia, and also has evidence of success in people who's B-cell lymphomas have relapsed after initial treatments. In this research study we are looking to see if ofatumumab is effective and safe in treating previously untreated B-cell NHL.

  • Conditions: follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma
  • Phase: II
  • Trial ID: NCT01239394
  • Protocol ID: 10-271

Not Enrolling

"A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination with PD-1/L1 Blockade in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer"

Trial Description: This is a Phase 2, single-arm, multi-institutional clinical trial designed to study the combination of CV301 with atezolizumab in the first-line treatment of UC not eligible for cisplatin-containing chemotherapy (Cohort 1) and in the second-line treatment of UC previously treated with standard first-line cisplatin-based chemotherapy (Cohort 2

  • Conditions: bladder cancer
  • Phase: II
  • Trial ID: NCT03628716
  • Protocol ID: 18-213

Not Enrolling

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab vedotin- HuMax-AXL-ADC) in patients with solid tumors

Trial Description: The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors

  • Conditions: cervical cancer, endometrial cancer, melanoma, non small cell lung cancer (nsclc), ovarian cancer, sarcoma, solid tumors, thyroid cancer
  • Phase: I/II
  • Trial ID: NCT02988817
  • Protocol ID: 18-183

Enrolling

Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Colorectal Cancer Survivors (Tools To Be Fit)

Trial Description: This clinical trial studies the effect of four different intervention components "tools" on body weight, nutrition, and physical activity in colorectal cancer survivors. Studies indicate that people with colorectal cancer whose nutrition and physical activity habits are consistent with the American Cancer Society's Nutrition and Physical Activity Guidelines may have longer disease-free survival. The four different intervention components may help patients with colon or rectal cancer adopt recommended health behaviors after they have completed treatment.

  • Conditions: stage i colon cancer ajcc v8, stage i rectal cancer ajcc v8, stage ii colon cancer ajcc v8, stage ii rectal cancer ajcc v8, stage iia colon cancer ajcc v8, stage iia rectal cancer ajcc v8, stage iib colon cancer ajcc v8, stage iib rectal cancer ajcc v8, stage iic colon cancer ajcc v8, stage iic rectal cancer ajcc v8, stage iii colon cancer ajcc v8, stage iii rectal cancer ajcc v8, stage iiia colon cancer ajcc v8, stage iiia rectal cancer ajcc v8, stage iiib colon cancer ajcc v8, stage iiib rectal cancer ajcc v8, stage iiic colon cancer ajcc v8, stage iiic rectal cancer ajcc v8
  • Phase: Not Applicable
  • Trial ID: NCT05056077
  • Protocol ID: 21-554

Enrolling

A Phase 2 Study of Avelumab in Combination with Bladder-Directed Radiation in Cisplatin-Ineligible Patients with Muscle-Invasive Urothelial Carcinoma of the Bladder

Trial Description: This research study is studying the effects of adding a certain type of immunotherapy to standard bladder-directed radiation as a treatment for muscle-invasive urothelial carcinoma of the bladder. The drug in this study is: Avelumab (also known as BAVENCIO

  • Conditions: bladder cancer, muscle invasive bladder cancer
  • Phase: II
  • Trial ID: NCT03747419
  • Protocol ID: 18-464

Not Enrolling

A Phase 2 Multicenter, Open-label Study of rucaparib as treatment for Solid tumors associated with Deleterious Mutations in Homologous Recombination Repair Genes

Trial Description: A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in patients with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes

  • Conditions: solid tumor
  • Phase: II
  • Trial ID: NCT04171700
  • Protocol ID: 19-756

Not Enrolling

Vitamin D Receptor Agonist Paricalcitol plus Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer

Trial Description: This research study is a two stage study which consists of a safety run-in phase and a randomized phase 2 study which include subjects with previously-untreated, metastatic pancreatic adenocarcinoma. In the run-in safety study, the safety of adding two formulations (IV or Oral) of paricalcitol to a standard chemotherapy program of gemcitabine and nab-paclitaxel will be evaluated. The randomized phase 2 study will evaluate the efficacy of paricalcitol when added to gemcitabine and nab-paclitaxel The drugs involved in this study are: - Paricalcitol - Gemcitabine - Nab

  • Conditions: pancreatic cancer
  • Phase: I/II
  • Trial ID: NCT03520790
  • Protocol ID: 18-021

Not Enrolling

A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination with AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors - OLAPCO (Olaparib Combinations)

Trial Description: The primary objective of this phase II trial is to determine tumor overall response rate (ORR) in molecularly selected patients with measurable disease as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST), before versus after 16 weeks of treatment across tumor types in each arm of the study

  • Conditions: cancer
  • Phase: II
  • Trial ID: NCT02576444
  • Protocol ID: 16-314

Enrolling

Phase I/II, Two-Part, Multicenter First-in-Human Study of DS-7300a in Subjects with Advanced Solid Malignant Tumors

Trial Description: This study is in one single group of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. The primary purpose of the parts are: - Dose Escalation Part: To evaluate the safety and tolerability and to determine the maximum tolerated dose and the recommended dose for expansion of DS-7300a. - Dose Expansion Part: To investigate the safety, tolerability and antitumor activity of DS-7300a when administered as a single agent. This study is expected to last approximately 5

  • Conditions: advanced solid tumor, malignant solid tumor
  • Phase: I/II
  • Trial ID: NCT04145622
  • Protocol ID: 20-725

Enrolling

Phase I trial of ASTX727 in recurrent/progressive non-enhancing IDH mutant gliomas

Trial Description: this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients

  • Conditions: neurological cancer
  • Phase: I
  • Trial ID: NCT03922555
  • Protocol ID: 18-631

Not Enrolling

A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)

Trial Description: This is a Phase 2, open-label, multi-center study to evaluate the efficacy and the safety/tolerability of poziotinib in seven patient cohorts for up to 603 previously treated and treatment-naïve NSCLC patients. Cohorts 3 and 4 were added with Amendment 1 and three additional cohorts were added with Amendment 2 (Cohorts 5, 6 and 7

  • Conditions: nsclc
  • Phase: II
  • Trial ID: NCT03318939
  • Protocol ID: 18-059

Enrolling

Pilot Study to Identify Transcriptional Targets of Vitamin D in patients with Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases Receiving Preoperative Vitamin D Supplementation.

Trial Description: This study seeks to learn more about the vitamin D receptor and its relationship to colon cancer. The Vitamin D receptor is found in colon cancer cells. When Vitamin D binds to the receptor in the cancer cells, it may stop cancer cells from growing abnormally and may cause cancer cell death. Vitamin D has been used in other research studies and information from those other research studies suggests that Vitamin D may help in the treatment of colon cancer. Participants will receive either high-dose vitamin D or standard-dose vitamin D. The study drug will be given 14-28 days prior to your surgery. The number of days will depend on when the surgery is scheduled.

  • Conditions: stage i-iii colon cancer, stage iv colon cancer with resectable liver metastases, stage colon cancer
  • Phase: Feasibility / Pilot
  • Trial ID: NCT02172651
  • Protocol ID: 14-091

Enrolling

A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors

Trial Description: A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors

  • Conditions: colorectal cancer, head and neck cancer, metastatic cancer, pancreatic cancer, solid tumor, urothelial carcinoma
  • Phase: I/II
  • Trial ID: NCT04666688
  • Protocol ID: 20-668